Antiatherosclerotic effects of ACE inhibitors: where are we now?
ACE inhibitors have been used extensively in the management of patients with hypertension and heart failure. Over the past decade, a large body of evidence has emerged indicating that ACE inhibition also favorably affects the vasculature, and that these effects are associated with improved patient outcomes. Such evidence is provided by several sources: (i) experimental studies, which demonstrate that in addition to blood pressure lowering, ACE inhibitors improve endothelial function and have a host of other beneficial effects on the arterial wall; (ii) epidemiologic studies, which link the renin-angiotensin-aldosterone system to increased risk for myocardial infarction, and (iii) clinical trials, which demonstrate that treatment with these agents reduces the risk for acute ischemic events, improves the function of the arterial endothelium and can retard the progression of the anatomic extent of atherosclerosis.
Lonn
E
E
McMaster University, Hamilton, Ontario, Canada.
D000806:Angiotensin-Converting Enzyme Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D001161:Arteriosclerosis / Q000175:diagnosis / Q000188:drug therapy* / Q000517:prevention & control*; D017023:Coronary Angiography; D004730:Endothelium, Vascular / Q000187:drug effects; D006801:Humans; D009203:Myocardial Infarction / Q000517:prevention & control; D016032:Randomized Controlled Trials as Topic; D018084:Ultrasonography, Interventional
D000806:Angiotensin-Converting Enzyme Inhibitors